In situ immunological characterization of Langerhans cells with monoclonal antibodies: Comparison with other dendritic cells in skin and lymph nodes

1984 ◽  
Vol 403 (4) ◽  
pp. 401-412 ◽  
Author(s):  
Elisabeth Ralfk�r ◽  
Harald Stein ◽  
Torben Plesner ◽  
Klaus Hou-Jensen ◽  
David Mason
Keyword(s):  
Dendritic Cells ◽  
Monoclonal Antibodies ◽  
Lymph Nodes ◽  
Langerhans Cells ◽  
Immunological Characterization

In situ demonstration of migration of dendritic cells released from rat small intestine to mesenteric lymph nodes

2001 ◽  
Vol 120 (5) ◽  
pp. A183-A183
Author(s):  
H KOBAYASHI ◽  
H NAGATA ◽  
S MIURA ◽  
T AZUMA ◽  
H SUZUKI ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Small Intestine ◽  
Lymph Nodes ◽  
Rat Small Intestine ◽  
Mesenteric Lymph Nodes ◽  
Mesenteric Lymph

Immunological characterization of riboflavin carrier proteins using monoclonal antibodies

1987 ◽  
Vol 24 (9) ◽  
pp. 969-974 ◽  
Author(s):  
Sandhya S. Visweswariah ◽  
Anjali A. Karande ◽  
P. Radhakantha Adiga
Keyword(s):  
Monoclonal Antibodies ◽  
Carrier Proteins ◽  
Immunological Characterization

scholarly journals Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy

PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0151008 ◽  
Author(s):  
Veronica Rainone ◽  
Cristina Martelli ◽  
Luisa Ottobrini ◽  
Mara Biasin ◽  
Gemma Texido ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Cancer Immunotherapy ◽  
Immunological Characterization ◽  
Tumour Lysate

scholarly journals Analysis of B-cell antigens in normal reactive lymphoid tissue using four B-cell monoclonal antibodies

Blood ◽  
1983 ◽  
Vol 62 (4) ◽  
pp. 775-783
Author(s):  
FM Hofman ◽  
E Yanagihara ◽  
B Byrne ◽  
R Billing ◽  
S Baird ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
B Cells ◽  
Lymph Nodes ◽  
B Cell ◽  
Germinal Center ◽  
Immunoperoxidase Method ◽  
Intense Staining ◽  
Normal Spleen ◽  
Reactive Hyperplasia

Lymph nodes from 13 cases of reactive hyperplasia were examined with four different monoclonal antibodies to B cells. B-1 recognizes an antigen of 30,000 daltons on B cells. CB-2 was prepared with normal spleen and binds to a glycolipid. BA-1 labels surface immunoglobulin- positive cells, but not T lymphocytes or monocytes. B-532 recognizes an antigenic determinant of 45,000 daltons. Using the immunoperoxidase method on frozen sections of reactive lymph nodes, the staining patterns of these four unique antibodies showed dramatic differences. B- 1 labeled 80%-90% of the germinal center cells and 10%-50% of the mantle region. Few interfollicular cells were positive. CB-2 stained predominantly in the mantle area (50%-90% positive cells), with moderate staining in the germinal center as well and less than 1% positive cells in the diffuse cortex. BA-1 exhibited predominant labeling in the mantle (50%-90%), with little staining in the germinal center. A large number of cells in the interfollicular, subcapsular, and medullary regions expressed the BA-1 antigen. The B-5 antibody demonstrated intense staining in the follicle (50%-95%). This staining often appeared to be polarized within the germinal center. The mantle zone demonstrated staining of 30%-50% of the cells. The different staining patterns of the B-cell antibodies, as demonstrated by the in situ distribution of positive cells within the lymph node, may reflect stages of development or activation of the B-cell population.

scholarly journals Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1082 ◽  
Author(s):  
Hubert ◽  
Gobbini ◽  
Bendriss-Vermare ◽  
Caux ◽  
Valladeau-Guilemond
Keyword(s):  
Dendritic Cells ◽  
T Cell Activation ◽  
Cell Activation ◽  
Human Tumor ◽  
High Dimensional ◽  
Prognostic Impact ◽  
In Situ Visualization ◽  
A Cell

The interaction between tumor cells and the immune system is considered to be a dynamic process. Dendritic cells (DCs) play a pivotal role in anti-tumor immunity owing to their outstanding T cell activation ability. Their functions and activities are broad ranged, triggering different mechanisms and responses to the DC subset. Several studies identified in situ human tumor-infiltrating DCs by immunostaining using a limited number of markers. However, considering the heterogeneity of DC subsets, the identification of each subtype present in the immune infiltrate is essential. To achieve this, studies initially relied on flow cytometry analyses to provide a precise characterization of tumor-associated DC subsets based on a combination of multiple markers. The concomitant development of advanced technologies, such as mass cytometry or complete transcriptome sequencing of a cell population or at a single cell level, has provided further details on previously identified populations, has unveiled previously unknown populations, and has finally led to the standardization of the DCs classification across tissues and species. Here, we review the evolution of tumor-associated DC description, from in situ visualization to their characterization with high-dimensional technologies, and the clinical use of these findings specifically focusing on the prognostic impact of DCs in cancers.

Sign in / Sign up

Export Citation Format

Share Document